Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery

JAMA

Volumn 277, Issue 8, 1997, Pages 646-650

  Bennett Guerrero, Elliott ^a   Ayuso, Liza ^b   Hamilton Davies, Colin ^c   White, William D ^d   Barclay, G Robin ^e   Smith, Peter K ^d   King, Sally A ^d   Muhlbaier, Lawrence H ^d   Newman, Pmark F ^d   Mythen, Michael G ^d  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY;

ANTIBODY DETECTION; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HEART VALVE SURGERY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LENGTH OF STAY; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

EID: 0031035328     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.8.646     Document Type: Article

References (51)

1. Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, Tex: American Heart Association; 1995:1-23.
2. Hammermeister KE, Burchfiel C, Johnson R, Grover FL. Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation. 1990;82:IV380-IV389.
3. Goris RJA, Boekhorst TPA, Nuytinck JKS, Gimbrère JSF. Multiple-organ failure: generalized autodestructive inflammation? Arch Surg. 1985;120: 1109-1115.
4. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: ACCP/SCCM consensus conference. Chest. 1992;101:1644-1655.
5. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
6. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318: 1481-1486.
7. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417-432.
8. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med. 1989;169:823-832.
9. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccahrides (endotoxins). J Exp Med. 1974; 140:797-811.
10. 2-IFN/IL-6 in man. J Immunol. 1989;142:2321-2324.
11. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE. Endotoxemia in human septic shock. Chest. 1991;99:169-175.
12. Andersen LW, Baek L, Degn H, Lehd J, Krasnik M, Rasmussen JP. Presence of circulating endotoxins during cardiac operations. J Thorac Cardiovasc Surg. 1987;93:115-119.
13. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA. 1996;275:1007-1012.
14. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1987; 93:832-837.
15. Martinez-Pellús AE, Merino P, Bru M, et al. Can selective decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med. 1993;21:1684-1691.
16. Watarida S, Mori A, Onoe M, et al. A clinical study on the effects of pulsatile cardiopulmonary bypass on the blood endotoxin levels. J Thorac Cardiovasc Surg. 1994;108:620-625.
17. Deitch EA, Berg R. Bacterial translocation from the gut: a mechanism of infection. J Burn Care Rehabil. 1987;8:475-482.
18. Deitch EA. Bacterial translocation of the gut flora. J Trauma. 1990;30:S184-S189.
19. Fink MP. Effect of critical illness on microbial translocation and gastrointestinal mucosa permeability. Semin Respir Infec. 1994;9:256-260.
20. Fink MP, Antonsson JB, Wang H, Rothschild HR. Increased intestinal permeability in endotoxic pigs. Arch Surg. 1991;126:211-218.
21. Hamilton-Davies C, Barclay GR, Machin SJ, Webb AR. Relationship between endotoxin immune status and outcome following cardiac valve surgery. Br J Anaesth. 1995;74:S34. Abstract.
22. Freeman R, Gould FK. Prevention of fever and gram negative infection after open heart surgery by antiendotoxin. Thorax, 1985;40:846-848.
23. Gould FK, Harvey JA, Dytrych JK. Antibody to endotoxin is associated with decreased frequency of postoperative infection. Am J Obstet Gynecol. 1989;160:317-319.
24. Barclay GR. Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure: a review. In: Levin J, Alving CR, Munford RS, Redl H, eds. Bacterial Endotoxins: Lipopolysaccharides From Genes to Therapy. New York, NY: Wiley-Liss; 1995:263-272.
25. Barclay GR, Scott BB. Serological relationships between Escherichia coli and Salmonella smooth-and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies. Infect Immun. 1987;55:2706-2714.
26. Whicher JT, Perry DE, Hobbs JR. An evaluation of the Hyland laser nephelometer PDQ system for the measurement of immunoglobulins. Ann Clin Biochem. 1978;15:77-85.
27. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation. 1989;79:I-3-I-12.
28. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
29. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley and Sons; 1989.
31. Hannan EL, Kilburn H, Racz M, Shields E, Chassin MR. Improving the outcomes of coronary artery bypass surgery in New York State. JAMA. 1994;271:761-766.
32. Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. JAMA. 1992;267:2344-2348.
33. O'Connor GT, Plume SK, Olmstead EM, et al. Multivariate prediction of in-hospital mortality associated with coronary artery bypass graft surgery. Circulation. 1992;85:2110-2118.
34. Tu JV, Jaglal SB, Naylor CD, et al. Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Circulation. 1995;91:677-684.
35. Luderitz O, Staub AM, Westphal O. Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol Rev. 1966; 30:192-255.
36. Volk WA, Benjamin DC, Kadner RJ, Parsons JT. Medical Microbiology. Philadelphia, Pa: JB Lippincott; 1986:396-398.
37. Poxton IR. Antibodies to lipopolysaccharide. J Immunol Methods. 1995;186:1-15.
38. Baumgartner JD. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clin North Am. 1991;5:915-927.
39. Evans ME, Pollack M, Koles NL, Hardegen NJ, Panopoulos D. Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. J Infect Dis. 1992;166:803-811.
40. Warren HS, Amato SF, Fitting C, et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med. 1993;177:89-97.
41. Quezado ZMN, Natanson C, Ailing DW, et al. A controlled trial of HA-1A in a canine model of gram-negative septic shock. JAMA. 1993;269:2221-2227.
42. Ziegler EJ, Fischer CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 1991;324:429-436.
43. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
44. Goldie AS, Fearon KCH, Ross JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 1995;274:172-177.
45. De Camp MM, Demling R. Posttraumatic multisystem organ failure. JAMA. 1988;260:530-534.
46. Rush BF, Sori AJ, Murphy TF, Smith S, Flanagan JJ, Machiedo GW. Endotoxemia and bacteremia during hemorrhagic shock. Ann Surg. 1988; 207:549-554.
47. Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma. 1991;31:629-638.
48. Ford EG, Baisden CE, Matteson ML, Picone AL. Sepsis after coronary bypass grafting: evidence for loss of the gut mucosal barrier. Ann Thorac Surg. 1991;52:514-517.
49. Munster AM, Smith-Meek M, Dickerson C, Winchurch RA. Translocation: incidental phenomenon or true pathology? Ann Surg. 1993;3:321-327.
50. Bion JF, Badger I, Crosby HA, et al. Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med. 1994;22:40-49.
51. Deitch EA, Morrison J, Berg R, Specian RD. Effect of hemorrhagic shock on bacterial translocation, intestinal morphology, and intestinal permeability in conventional and antibiotic-decontaminated rats. Crit Care Med. 1990;18:529-536.